Evidence map›Paper›PMID 33568697›Full record

ArticleScientific reports2021

An arylthiazyne derivative is a potent inhibitor of lipid peroxidation and ferroptosis providing neuroprotection in vitro and in vivo.

Meike Hedwig Keuters, Velta Keksa-Goldsteine, Hiramani Dhungana, Mikko T Huuskonen, Yuriy Pomeshchik, Ekaterina Savchenko, Paula K Korhonen, Yajuvinder Singh, Sara Wojciechowski, Šárka Lehtonen and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Ferroptosis inhibitors: mechanisms of action and therapeutic potential.Cellular and molecular life sciences : CMLS · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Ferroptosis inhibitors: past, present and future.Frontiers in pharmacology · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Progranulin released from microglial lysosomes reduces neuronal ferroptosis after cerebral ischemia in mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Meike Hedwig KeutersA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Velta Keksa-GoldsteineA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Hiramani DhunganaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Mikko T HuuskonenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Yuriy PomeshchikA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Ekaterina SavchenkoA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Paula K KorhonenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Yajuvinder SinghA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Sara WojciechowskiA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Šárka LehtonenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Katja M KanninenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Tarja MalmA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Jouni SirviöAranda Pharma Ltd., Kuopio, Finland.
Anu MuonaAranda Pharma Ltd., Kuopio, Finland.
Milla KoistinahoAranda Pharma Ltd., Kuopio, Finland.
Gundars GoldsteinsA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Jari KoistinahoA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. jari.koistinaho@helsinki.fi.
University of Eastern Finland · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid peroxidation-initiated ferroptosis is an iron-dependent mechanism of programmed cell death taking place in neurological diseases. Here we show that a condensed benzo[b]thiazine derivative small molecule with an arylthiazine backbone (ADA-409-052) inhibits tert-Butyl hydroperoxide (TBHP)-induced lipid peroxidation (LP) and protects against ferroptotic cell death triggered by glutathione (GSH) depletion or glutathione peroxidase 4 (GPx4) inhibition in neuronal cell lines. In addition, ADA-409-052 suppresses pro-inflammatory activation of BV2 microglia and protects N2a neuronal cells from cell death induced by pro-inflammatory RAW 264.7 macrophages. Moreover, ADA-409-052 efficiently reduces infarct volume, edema and expression of pro-inflammatory genes in a mouse model of thromboembolic stroke. Targeting ferroptosis may be a promising therapeutic strategy in neurological diseases involving severe neuronal death and neuroinflammation.

Indexed as

AnimalsApoptosisCell DeathFerroptosisGlutathioneIronLipid PeroxidationMicrogliaNeuroprotectionPhospholipid Hydroperoxide Glutathione PeroxidaseProtective AgentsGlutathioneIronPhospholipid Hydroperoxide Glutathione PeroxidaseProtective Agents

Identifiers

PMID33568697
PMCPMC7876050
OpenAlexW3128836575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.